Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07590193 | A Trial Evaluating AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus | PHASE1 | NOT YET_RECRUITING | 162 | — | — | Jun 15, 2026 | Oct 2, 2027 | May 15, 2026 | - | — |
| Arm | Type | Description |
|---|---|---|
| Part A: Single Ascending Dose (SAD) | EXPERIMENTAL | Participants will receive single ascending doses of AMG 127 via subcutaneous (SC) injection. One cohort will receive a single dose of AMG 127 as an intravenous (IV) infusion. |
| Part B: Multiple Ascending Dose (MAD) | EXPERIMENTAL | Participants will receive multiple ascending doses of AMG 127 via SC injection. |
| Part C: Proof of Mechanism (PoM) | EXPERIMENTAL | Participants will receive multiple doses of AMG 127 via SC injection. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a matching placebo as either a SC injection or as an IV infusion. |
| Name | Type | Description |
|---|---|---|
| AMG 127 | DRUG | AMG127 will be administered as either a SC injection or as an IV infusion. |
| Placebo | DRUG | Placebo will be administered as either a SC injection or as an IV infusion. |
Inclusion Criteria for Part A and B * Participant must be 18-65 years of age * Participant must be overtly healthy Inclusion Criteria for Part C * Participant must be 40-75 years of age * Confirmed diagnoses of T2DM Exclusion Criteria for Part A and B * History of hypotension, syncope, or ortho...